Citations

Clear

750 citation(s) found for "Lowe, Val".

P4‐249: STRESS COPING ABILITY ASSOCIATED WITH TAU IN PRECLINICAL ALZHEIMER'S DISEASE
Arenaza‐Urquijo, Eider M. , Przybelski, Scott A. , Lowe, Val J. , Reddy, Ashritha L., Petersen, Ronald C. , Arenaza-Urquijo, Eider M , Machulda, Mary M. , Knopman, David S. , Mielke, Michelle M. , Reddy, Ashritha L., Geda, Yonas E. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_26 | Pages: No page available

10.1016/j.jalz.2019.06.3912 Get It

P3‐427: MILD COGNITIVE IMPAIRMENT PROGRESSING TO DEMENTIA WITH LEWY BODIES: REGIONAL ATROPHY RATES AND RELATIONSHIP TO AV‐1451 UPTAKE
Przybelski, Scott A. , Lesnick, Timothy G. , Graff‐Radford, Jonathan , Savica, Rodolfo , Drubach, Daniel A., Fields, Julie A. , Graff‐Radford, Neill R. , Lowe, Val J. , Petersen, Ronald C. , Nedelská, Zuzana , Boeve, Bradley F. , Ferman, Tanis J. , Senjem, Matthew L. , Knopman, David S. , Jones, David T. , Jack, Clifford R. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3461 Get It

P3‐411: ANALYSIS OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH IDIOPATHIC REM SLEEP BEHAVIOR DISORDER
Maltais, Daniela D., Miyagawa, Toji , Przybelski, Scott A. , Jordan, Lennon, Lesnick, Timothy G. , Louis, E. St., Silber, Michael H. , Graff‐Radford, Jonathan , Savica, Rodolfo , Drubach, Daniel A., Knopman, David S. , Petersen, Ronald C. , Fields, Julie A. , Forsberg, Leah K. , Allen, Laura A., Lowe, Val J. , Min, Hoon-Ki Paul , Jones, David T. , Knopman, David S. , Machulda, Mary M. , Nedelská, Zuzana , Boeve, Bradley F. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3445 Get It

P3‐396: VARIABILITY IN MRI AND PET MEASUREMENTS INTRODUCED BY CHANGE IN MRI VENDOR
Wiste, Heather J. , Gunter, Jeffrey L. , Lowe, Val J. , Petersen, Ronald C. , Schwarz, Christopher G. , Senjem, Matthew L. , Knopman, David S. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2019.06.3429 Get It

P1‐376: LONG‐TERM NSAID THERAPY IN OLDER ADULTS: EFFECTS ON AT(N)V IMAGING BIOMARKERS
Przybelski, Scott A. , Graff‐Radford, Jonathan , Lowe, Val J. , Petersen, Ronald C. , Ramanan, Vijay K. , Castillo, Anna , Mielke, Michelle M. , Knopman, David S. , Jack, Clifford R. , Vemuri, Prashanthi

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2019.06.931 Get It

P1‐367: COMPARISON OF IOFLUPANE‐SPECT FINDINGS USING DATQUANT IN PATIENTS WITH ALZHEIMER'S DISEASE DEMENTIA AND DEMENTIA WITH LEWY BODIES
Miyagawa, Toji , Przybelski, Scott A. , Maltais, Daniela D., Jordan, Lennon, Lesnick, Timothy G. , Graff‐Radford, Jonathan , Savica, Rodolfo , Drubach, Daniel A., Petersen, Ronald C. , Fields, Julie A. , Forsberg, Leah K. , Allen, Laura A., Parisi, Joseph E., Lowe, Val J. , Min, Hoon-Ki Paul , Jones, David T. , Knopman, David S. , Machulda, Mary M. , Nedelská, Zuzana , Murray, Melissa E. , Dickson, Dennis W. , Boeve, Bradley F. , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 18, 2019 | Volume: 15 | Issue: 7S_Part_7 | Pages: No page available

10.1016/j.jalz.2019.06.922 Get It

PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.
Micallef, Ivana N. , Nikcevich, Daniel A., Kurtin, Paul J. , Cannon, Michael W., Flynn, Patrick J. , Soori, Gamini S. , Lowe, Val J. , Wiseman, Gregory A., Maurer, Matthew J. , Witzig, Thomas E.

Mayo Clinic

Blood | October 12, 2019 | Volume: 114 | Issue: 22 | Pages: 137-137

10.1182/blood.v114.22.137.137 Get It

Abstract Abstract 137 Background: FDG-PET/CT after 2–4 cycles of chemotherapy has been shown to be predictive of outcome in patients with aggressive lymphoma. This multicenter NCCTG phase II study was carried out to assess efficacy of ER-CHOP in newly diagnosed DLBCL; functional response as measured by FDG-PET/CT was done after 2 cycles and after 6 cycles of therapy. Methods: Patients received immunochemotherapy on the following schedule: epratuzumab 360 mg/m2, rituximab 375 mg/m2, and standard dose CHOP every 3 weeks for 6 cycles. FDG-PET/CT was done after 2 cycles and again after 6 cycles of therapy. All PET scans were centrally reviewed by an expert in nuclear medicine who was blinded to the outcome of the patients. Results: 107 patients were accrued from Feb 2006 to Aug 2007. 27 patients were ineligible resulting in 80 eligible patients. Baseline patient characteristics for the eligible patients included median age 60 (range 21–82); 56% were male. 80% had advanced stage; 73% had an elevated LDH. Performance score was 0–1 in 71 pts and 2–3 in 9 pts. IPI was 0–1 in 18 pts (23%), 2 in 22 pts (28%), 3 in 29 pts (36%) and 4–5 in 11 pts (14%). PET scans were available on 76 patients (95%); 3 patients completed treatment but scans were unavailable and 1 died prior to cycle 2 PET. The PET CR rate after 2 cycles was 79%. The PET CR rate after 6 cycles was 90%. Using an intent to treat (ITT) analysis, 67 patients (87%) achieved PET CR of which 61 (79%) also completed all 6 cycles of treatment. Based on interim PET after 2 cycles, the EFS at 24 months (EFS24) was 73% for the PET negative patients vs 60% for the PET positive patients (p=0.25); OS at 24 months (OS24) was 83% vs 73% for the PET negative and positive pts, respectively (p=0.17). In comparison, EFS24 for patients with a negative PET after 6 cycles was 80% vs 57% for those with a positive PET (p=0.11); OS24 was 92% vs 57%, respectively (p=0.01). In intent to treat (ITT) analysis, patients that achieved a functional CR had improved overall survival (OS24 = 84%) and event free survival (EFS24 = 74%) compared to patients that failed to achieve a functional CR (OS24 = 50%, EFS24 = 40%, p=0.01 and p=0.006 respectively). Conclusions: ER-CHOP every 21 days × 6 cycles results in a functional CR rate of 87%. Early PET scan during therapy does not significantly predict outcome. Achievement of PET negativity by completion of therapy is associated with a good outcome Disclosures: No relevant conflicts of interest to declare.
Amyloid, Vascular, and Resilience Pathways Associated with Cognitive Aging
Vemuri, Prashanthi , Lesnick, Timothy G. , Przybelski, Scott A. , Reid, Robert I. , Graff‐Radford, Jonathan , Lowe, Val J. , Petersen, Ronald C. , Jack, Clifford R. , Reid, Robert I , Jack, Clifford R , Vemuri, Prashanthi , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M.

Mayo Clinic

Annals of Neurology | September 11, 2019 | Volume: 86 | Issue: 6 | Pages: 866-877

10.1002/ana.25600 | PMID 31509621 Get It

ObjectiveTo investigate the multifactorial processes underlying cognitive aging based on the hypothesis that multiple causal pathways and mechanisms (amyloid, vascular, and resilience) influence longitudinal cognitive decline in each individual through worsening brain health.MethodsWe identified 1,230 elderly subjects (aged ≥50 years) with an average of 4.9 years of clinical follow‐up and with amyloid positron emission tomography, diffusion tensor imaging, and structural magnetic resonance imaging scans from the population‐based Mayo Clinic Study of Aging. We examined imaging markers of amyloid and brain health (white matter microstructural integrity and cortical thinning), systemic vascular health preceding the imaging markers, and early to midlife intellectual enrichment to predict longitudinal cognitive trajectories. We used latent growth curve models for modeling longitudinal cognitive decline.ResultsAll the pathways (amyloid, vascular, resilience) converged through their effects on cortical thinning and worsening cognition and together explained patterns in cognitive decline. Resilience and vascular pathways (aging process, sex differences, education/occupation, and systemic vascular health) had significant impact on white matter microstructural integrity. Education/occupation levels contributed to white matter integrity through systemic vascular health. Worsening white matter integrity contributed to significant cortical thinning and subsequently longitudinal cognitive decline. Baseline amyloidosis contributed to a significant proportion of cognitive decline that accelerated with longer follow‐up times, and its primary impact was through cortical thinning.InterpretationWe developed an integrated framework to help explain the dynamic and complex process of cognitive aging by considering key causal pathways. Such an approach is important for both better comprehension of cognitive aging processes and will aid in the development of successful intervention strategies. ANN NEUROL 2019;86:866–877
The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes
Jack, Clifford R. , Wiste, Heather J. , Botha, Hugo , Weigand, Stephen D. , Therneau, Terry M. , Graff‐Radford, Jonathan , Ferman, Tanis J. , Boeve, Bradley F. , Kantarci, Kejal , Lowe, Val J. , Vemuri, Prashanthi , Fields, Julie A. , Senjem, Matthew L. , Gunter, Jeffrey L. , Petersen, Ronald C. , Jack, Clifford R , Boeve, Brad , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal , Botha, Hugo , Ferman, Tanis J , Knopman, David S. , Jones, David T. , Mielke, Michelle M. , Machulda, Mary M. , Schwarz, Christopher G.

Mayo Clinic

Brain | August 28, 2019 | Volume: 142 | Issue: 10 | Pages: 3230-3242

10.1093/brain/awz268 | PMID 31501889 Get It

See Gordon and Tijms (doi:10.1093/brain/awz278) for a scientific commentary on this article. Jack et al. examine relationships between the bivariate distribution of β-amyloid and tau on PET and established neurocognitive clinical syndromes. Amyloidosis appears to be required for high levels of 3R/4R tau deposition. Whereas abnormal amyloid PET is compatible with normal cognition, highly abnormal tau PET is not.
Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework
Jack, Clifford R. , Therneau, Terry M. , Weigand, Stephen D. , Wiste, Heather J. , Vemuri, Prashanthi , Lowe, Val J. , Roberts, Rosebud O., Graff‐Radford, Jonathan , Gunter, Jeffrey L. , Senjem, Matthew L. , Rocca, Walter A. , Petersen, Ronald C. , Jack, Clifford R , Vemuri, Prashanthi , Senjem, Matthew L , Knopman, David S. , Mielke, Michelle M. , Machulda, Mary M. , Jones, David T. , Schwarz, Christopher G.

Mayo Clinic

JAMA Neurology | July 15, 2019 | Volume: 76 | Issue: 10 | Pages: 1174

10.1001/jamaneurol.2019.1971 | PMID 31305929 Get It